HUMA vs. IMCR, ANIP, DYN, INDV, AMPH, ARDX, ETNB, EVO, OCUL, and GPCR
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), 89bio (ETNB), Evotec (EVO), Ocular Therapeutix (OCUL), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs.
Humacyte (NASDAQ:HUMA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 11.2% of Humacyte shares are owned by insiders. Comparatively, 9.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Humacyte has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Humacyte's return on equity.
Humacyte presently has a consensus target price of $13.71, indicating a potential upside of 376.19%. Immunocore has a consensus target price of $65.64, indicating a potential upside of 123.86%. Given Humacyte's stronger consensus rating and higher possible upside, equities analysts plainly believe Humacyte is more favorable than Immunocore.
Immunocore has higher revenue and earnings than Humacyte. Immunocore is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunocore had 4 more articles in the media than Humacyte. MarketBeat recorded 9 mentions for Immunocore and 5 mentions for Humacyte. Immunocore's average media sentiment score of 1.42 beat Humacyte's score of 0.71 indicating that Immunocore is being referred to more favorably in the news media.
Immunocore received 31 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 73.68% of users gave Immunocore an outperform vote while only 69.64% of users gave Humacyte an outperform vote.
Humacyte has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
Summary
Immunocore beats Humacyte on 11 of the 19 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 3/26/2025 by MarketBeat.com Staff
